Asia Pacific Skin Cancer: Increasing Demand For The Better Treatment of The Cancer is Projected to Uplift The Market at a CAGR of 7.80% During The Forecasted Period 2022-2030

Pune, India, December 2022/MRFR Press Release/- Market Research Future has a half cooked research report on the Asia Pacific skin cancer market.

Market Highlights

Cancer is becoming one of the major problems across the globe. Different types of cancer are been registered around the globe, but skin cancer is considered as one of the most common types of cancer. Over 90% of skin cancer caused due to exposure to ultraviolet radiation from the sun. These ultraviolet radiations are increasing continuously due to reducing ozone level.

There are three major types of skin cancer namely basal cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. Exposure to the radiation during childhood can cause melanomas and basal-cell cancers. People with light skin are more susceptible to the skin cancer.

The Asia Pacific skin cancer market is driven by increasing prevalence of skin cancer, the presence of developing economies and increasing government support. Australia accounts for the largest market share owing to a huge number of a patient having skin cancer. While adverse effect associated with the treatment, long approval time for the drugs, and strict regulatory policies may restrain the growth of the market over the corresponding period.

The Asia Pacific Skin Cancer Market is expected to reach USD 602.4 Million by 2030 at 7.80% CAGR during the forecast period 2022-2030

Regional Analysis

Australia dominates the Asia Pacific skin cancer market owing to exposure to UV radiation in sunlight, extensive use of commercial solariums, believe in tanning skin. According to Cancer Council Australia, Approximately, two in three Australians are likely to diagnose with skin cancer by the time they are 70 years old. Additionally above 750,000 people treated with skin cancer every year.

Japan accounts for the second largest market, where 20-25 cases of every 100,000 people are diagnosed with skin cancer. China is the third largest market due to huge population base, rapidly changing the economy, and increasing healthcare expenditure. The incidence of skin cancer in China per 100,000 population is 11-12 cases.

Countries like India, Republic of Korea, and rest of the Asia Pacific also showing significant growth in the skin cancer cases owing to increasing ultraviolet radiation from the sun.

Segmentation

Asia Pacific skin cancer market is segmented on the basis of type, by treatment, and by end users. On the basis of the type, it is segmented into basal cell carcinoma, squamous-cell carcinoma, and melanoma. On the basis of the treatment, it is segmented into non-invasive, chemotherapy, surgical, and other. Furthermore, non-invasive treatments are segmented into laser therapy, radiotherapy, photodynamic therapy, cryotherapy, and others, chemotherapy is segmented into systemic and targeted, and Surgical treatment are segmented into photodynamic therapy, cryosurgery, Mohs micrographic surgery, and others. On the basis of end users, the market is segmented into hospital and clinics, diagnostic centers, cancer research institute, and other.

Key Players

Some of key the players in the market are F. Hoffmann-la Roche Ltd. (Switzerland), Novartis International AG (Switzerland), Sun Pharma Industries Ltd. (India), Elekta AB (Sweden), Varian Medical Systems Inc. (US), Cannabis Science Inc. (US), Cellceutix Corp. (US), LEO Pharma A/S (Denmark), Moberg Pharma AB (Sweden), Mylan Pharmaceutical Inc. (US), Oncothyreon Inc. (US), Eli Lilly and Co. (US), Bristol Myers Squibb Co. (US), Boehringer Ingelheim GmbH (Germany), Aqua Pharmaceuticals LLC (US), Valeant Pharmaceuticals Inc (Canada), Meda AB (US), iCAD Inc. (Sweden), and Merck & Co. Inc. (US).

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Asia Pacific Skin Cancer Market Research Report